• Shire Settles All Pending Litigation with Actavis and Watson concerning INTUNIV®

    Philadelphia, PA, United States – April 25, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG), announces that its subsidiary, Shire LLC, has settled all pending litigation with Actavis, Inc., Actavis LLC, and Actavis Elizabeth LLC (collectively “Actavis”) and Watson Laboratories, Inc.-Florida, Watson Pharma, Inc. and ANDA, Inc. (collectively “Watson”) in connection with Actavis’ and Watson’s Abbreviated New Drug Applications (“ANDAs”) for generic versions of Shire’s INTUNIV® ( guanfacine hydrochloride) for the treatment of Attention Deficit Hyperactivity Disorder.
  • Shire LLP v. Corepharma LLP

    July 14, 2009, Frommer Lawrence & Haug LLP obtained a favorable settlement on behalf of its client, Shire LLP (“Shire”). The settlement put to end a years-long litigation with Corepharma LLP (“Corepharma”) in connection with Corepharma’s Abbreviated New Drug Application and its attempt to market generic versions of Shire’s Carbatrol® for the treatment of epilepsy and trigeminal neuralgia.
  • Shire Pharmaceuticals v. Barr Laboratories; Shire Laboratories v. Impax Laboratories

    FLH’s successful representation of Shire Laboratories Inc. since February 2003 lead to the August 2006 settlements of Hatch-Waxman litigations pending in the Southern District of New York, involving three Shire patents and defendant Barr Laboratories’ efforts to market generic versions of Shire’s Adderall XR® Attention Deficit Hyperactivity Disorder (“ADHD”) products.